Tarlatamab vs chemo for advanced NEC after one prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is a poorly differentiated neuroendocrine carcinoma (NEC) that has progressed after one course of platinum-based chemotherapy.
- At least 1% of your tumor cells must express the protein DLL3 (this is checked on a tissue sample).
- You must have advanced cancer that cannot be removed by surgery and at least one measurable tumor spot per standard scans (CT/MRI).
- You are age 18 or older, have a life expectancy over 12 weeks, and are healthy enough to perform your daily activities (ECOG 0-1).
- You have adequate kidney (creatinine clearance >50 mL/min), liver, and blood counts, and have recovered from side effects of prior therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This study tests an investigational drug called tarlatamab in people with a rare type of cancer called neuroendocrine carcinoma that started in the female reproductive tract (cervix, vulva, or vagina). The goal is to see if tarlatamab can shrink or control the cancer. To participate, your cancer must have progressed after at least one line of platinum-based chemotherapy. You must also have measurable disease and be willing to provide a tumor sample.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.